Skip to main content

March 2018, Vol 11, Ninth Annual Payers' Guide

Payers' Guide, FDA Approvals

Gocovri (Amantadine) First Drug Approved for Dyskinesia in Patients with Parkinson’s Disease

Payers' Guide, FDA Approvals

Idhifa (Enasidenib), First-in-Class IDH2 Inhibitor, Approved for Relapsed Acute Myeloid Leukemia with IDH2 Mutation

Payers' Guide, FDA Approvals

Imbruvica (Ibrutinib) First Drug Approved Specifically for Marginal-Zone Lymphoma and for Chronic Graft-versus-Host Disease

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Imfinzi (Durvalumab) a New PD-L1 Inhibitor Approved for the Treatment of Advanced or Metastatic Urothelial Cancer

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Kevzara (Sarilumab), a New IL-6 Receptor Antagonist, Approved for Active Rheumatoid Arthritis

Payers' Guide, FDA Approvals

Kisqali (Ribociclib): Second CDK4/CDK6 Inhibitor Approved for Postmenopausal Women with HR-Positive, HER2-Negative Advanced Breast Cancer

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Kymriah (Tisagenlecleucel) for Young Patients with Acute Lymphoblastic Leukemia: First FDA-Approved Gene Therapy

Payers' Guide, FDA Approvals

Nerlynx (Neratinib) First Extended Adjuvant Therapy Approved for HER2-Positive Breast Cancer

Payers' Guide, FDA Approvals

Revlimid (Lenalidomide) First Drug Approved for Post-Transplant Maintenance Therapy in Multiple Myeloma

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Shingrix (Zoster Vaccine Recombinant) a New Vaccine Approved for Herpes Zoster Prevention in Older Adults

Lisa A. Raedler, PhD, RPh

Page 2 of 4
Results 11 - 20 of 31